Deals and Financings   Zai Lab of Shanghai is conducting an $845 million Hong Kong IPO, a secondary listing for the company that already has a $6.2 billion capitalization on NASDAQ; Beijing-based Biocytogen completed a $142 million Series D+ round for its gene-modified animal model CRO operations; LinkDoc Technology, a Beijing oncology big data company, raised $103 million in a Series D+ funding round; Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired China rights to an aesthetic product from Israel 's Raziel Therapeutics in a $74 million agreement; XWPharma of Wuhan completed a $40 million Series C financing to develop its portfolio of novel neurobiology candidates; Singleron Bio, a Nanjing-Suzhou start-up developing its Gexscope® single-cell multiplex analysis technology, completed a $30 million Series A round; Forerunner Medical ( Shanghai ) closed a Series B funding that raised at least $28 million for its minimally invasive ablation/coagulation medical devices; GenScript ProBio, a Nanjing CDMO, agreed to license a bispecific antibody to REMD Bio for an undisclosed target; Yufan Bio of Xi'an partnered with Abound Bio of Pittsburgh to develop novel CAR-T technologies; Covid-19 Pandemic   The Fosun Pharma mRNA vaccine for COVID-19 could complete its Phase III trials in October, according to the company; Trials and Approvals Everest Medicines of Shanghai reported positive top-line safety results from a China Phase I trial of taniborbactam in multi-drug resistant (MDR) pathogens; Shanghai 's I-Mab and MorphoSys AG of Munich have permission to start US trials of an anti-C5aR1 antibody in solid tumors; A scentage Pharma of Suzhou was granted Orphan Drug Designation in the US for a novel MDM2-p53 inhibitor to treat gastric cancer. Stock Symbols: (NSDQ: ZLAB) (SHA: 600196; HK: 02196) (NSDQ: IMAB) (FSE: MOR) (HK: 6855) Share this with colleagues: // //